Cbd oil for dogs pubmed

Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis

The aim of this study was to evaluate the efficacy of oral transmucosal (OTM) cannabidiol (CBD), in addition to a multimodal pharmacological treatment for chronic osteoarthritis-related pain in dogs. Twenty-one dogs were randomly divided into two groups: in group CBD (n = 9), OTM CBD (2 mg kg -1 every 12 h) was included in the therapeutic protocol (anti-inflammatory drug, gabapentin, amitriptyline), while in group C (n = 12), CBD was not administered. Dogs were evaluated by owners based on the Canine Brief Pain Inventory scoring system before treatment initiation (T0), and one (T1), two (T2), four (T3) and twelve (T4) weeks thereafter. Pain Severity Score was significantly lower in CBD than in C group at T1 (p = 0.0002), T2 (p = 0.0043) and T3 (p = 0.016). Pain Interference Score was significantly lower in CBD than in C group at T1 (p = 0.0002), T2 (p = 0.0007) and T4 (p = 0.004). Quality of Life Index was significantly higher in CBD group at T1 (p = 0.003). The addition of OTM CBD showed promising results. Further pharmacokinetics and long-term studies in larger populations are needed to encourage its inclusion into a multimodal pharmacological approach for canine osteoarthritis-related pain.

Keywords: Canine Brief Pain Inventory; cannabidiol; chronic pain; dogs; oral transmucosal administration; osteoarthritis; pain management.

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, Brown H, Berthelsen ES, Wakshlag JJ. Gamble LJ, et al. Front Vet Sci. 2018 Jul 23;5:165. doi: 10.3389/fvets.2018.00165. eCollection 2018. Front Vet Sci. 2018. PMID: 30083539 Free PMC article.

See also  What cbd oil for pain

Perry MS. Perry MS. Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671. Epilepsy Curr. 2019. PMID: 30955420 Free PMC article.

Yu CHJ, Rupasinghe HPV. Yu CHJ, et al. Res Vet Sci. 2021 Nov;140:38-46. doi: 10.1016/j.rvsc.2021.08.001. Epub 2021 Aug 8. Res Vet Sci. 2021. PMID: 34391060 Review.

Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, Dunner K Jr, Salimpour P, Decker WK, Halpert MM. Verrico CD, et al. Pain. 2020 Sep 1;161(9):2191-2202. doi: 10.1097/j.pain.0000000000001896. Pain. 2020. PMID: 32345916 Free PMC article. Clinical Trial.

Franco V, Perucca E. Franco V, et al. Drugs. 2019 Sep;79(13):1435-1454. doi: 10.1007/s40265-019-01171-4. Drugs. 2019. PMID: 31372958 Review.

Cited by 6 articles

Shilo-Benjamini Y, Cern A, Zilbersheid D, Hod A, Lavy E, Barasch D, Barenholz Y. Shilo-Benjamini Y, et al. Front Vet Sci. 2022 Apr 28;9:892306. doi: 10.3389/fvets.2022.892306. eCollection 2022. Front Vet Sci. 2022. PMID: 35573415 Free PMC article.

Mosley C, Edwards T, Romano L, Truchetti G, Dunbar L, Schiller T, Gibson T, Bruce C, Troncy E. Mosley C, et al. Front Vet Sci. 2022 Apr 26;9:830098. doi: 10.3389/fvets.2022.830098. eCollection 2022. Front Vet Sci. 2022. PMID: 35558892 Free PMC article. Review.

Morris EM, Kitts-Morgan SE, Spangler DM, Ogunade IM, McLeod KR, Harmon DL. Morris EM, et al. Front Vet Sci. 2021 Jul 16;8:685606. doi: 10.3389/fvets.2021.685606. eCollection 2021. Front Vet Sci. 2021. PMID: 34336977 Free PMC article.

Morris EM, Kitts-Morgan SE, Spangler DM, Gebert J, Vanzant ES, McLeod KR, Harmon DL. Morris EM, et al. Front Vet Sci. 2021 Apr 29;8:645667. doi: 10.3389/fvets.2021.645667. eCollection 2021. Front Vet Sci. 2021. PMID: 33996972 Free PMC article.

See also  Can you use any cbd oil for baking

Kulpa JE, Paulionis LJ, Eglit GM, Vaughn DM. Kulpa JE, et al. J Feline Med Surg. 2021 Dec;23(12):1162-1175. doi: 10.1177/1098612X211004215. Epub 2021 Mar 26. J Feline Med Surg. 2021. PMID: 33769105 Free PMC article.

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs

Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA). Methods: Single-dose pharmacokinetics was performed using two different doses of CBD enriched (2 and 8 mg/kg) oil. Thereafter, a randomized placebo-controlled, veterinarian, and owner blinded, cross-over study was conducted. Dogs received each of two treatments: CBD oil (2 mg/kg) or placebo oil every 12 h. Each treatment lasted for 4 weeks with a 2-week washout period. Baseline veterinary assessment and owner questionnaires were completed before initiating each treatment and at weeks 2 and 4. Hematology, serum chemistry and physical examinations were performed at each visit. A mixed model analysis, analyzing the change from enrollment baseline for all other time points was utilized for all variables of interest, with a p ≤ 0.05 defined as significant. Results: Pharmacokinetics revealed an elimination half-life of 4.2 h at both doses and no observable side effects. Clinically, canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity (p < 0.01) with CBD oil. Veterinary assessment showed decreased pain during CBD treatment (p < 0.02). No side effects were reported by owners, however, serum chemistry showed an increase in alkaline phosphatase during CBD treatment (p < 0.01). Clinical significance: This pharmacokinetic and clinical study suggests that 2 mg/kg of CBD twice daily can help increase comfort and activity in dogs with OA.

See also  Is cbd oil good for knee pain

Keywords: CBD oil; canine; cannabidiol; hemp; osteoarthritis; pharmacokinetic.

Figures

Box-and-whisker plot of serum alkaline…

Box-and-whisker plot of serum alkaline phosphatase (ALP) activity at each time for treatment…

Box-and-whisker plot of serum alkaline phosphatase (ALP) activity at each time for treatment and placebo oils. Box represents the mean and 25th and 75th percentile and the whiskers represent the 99th and 1st percentiles. * Indicates a significant difference (p < 0.05) from week 0 CBD treatment.